Mechanisms of vascular injury from drug-eluting stents

Drug Discovery Today: Disease Mechanisms

Volumn 4, Issue 3, 2007, Pages 141-146

  Sarembock, Ian J ^a   Kereiakes, Dean J ^a  

^a Ohio Heart and Vascular Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PACLITAXEL; RAPAMYCIN;

ARTERY WALL; BLOOD VESSEL INJURY; CLINICAL TRIAL; DRUG ELUTING STENT; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RELEASE; ENDOTHELIAL DYSFUNCTION; EPITHELIZATION; FIBRIN DEPOSITION; HEALING IMPAIRMENT; HUMAN; IN-STENT RESTENOSIS; INFLAMMATION; MATERIAL COATING; MITOSIS INHIBITION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SMOOTH MUSCLE FIBER; STENT THROMBOSIS; THROMBOSIS; TISSUE NECROSIS; TREATMENT INDICATION;

EID: 47049120685     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2007.10.007     Document Type: Review

References (40)

1. Virmani R., et al. Drug eluting stents: are human and animal studies comparable?. Heart 89 (2003) 133-138
2. Tanner F.C., et al. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation 101 (2000) 2022-2025
3. Sun J., et al. Role for p27(Kip1) in vascular smooth muscle cell migration. Circulation 103 (2001) 2967-2972
4. Abal M., et al. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr. Cancer Drug Targets 3 (2003) 193-203
5. Parry T.J., et al. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur. J. Pharmacol. 524 (2005) 19-29
6. Axel D.I., et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96 (1997) 636-645
7. Vinals F., et al. p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation. J. Biol. Chem. 274 (1999) 26776-26782
8. Fukuda D., et al. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation 111 (2005) 926-931
9. Kotani J., et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J. Am. Coll. Cardiol. 47 (2006) 2108-2111
10. Joner M., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48 (2006) 193-202
11. Finn A.V., et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1500-1510
12. Heldman A.W., et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103 (2001) 2289-2295
13. Drachman D.E., et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J. Am. Coll. Cardiol. 36 (2000) 2325-2332
14. Farb A., et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 04 (2001) 473-479
15. Goode, J. (2003) FDA Summary: Taxus express paclitaxel-eluting monorail and over-the-wire coronary stent systems-PMA for marketing approval: U.S. Food and Drug Administration, 23 October 2003
16. Togni M., et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J. Am. Coll. Cardiol. 46 (2005) 231-236
17. Hofma S.H., et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur. Heart J. 27 (2006) 166-170
18. Stahli B.E., et al. Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ. Res. 99 (2006) 149-155
19. Steffel J., et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 112 (2005) 2002-2011
20. Muldowney III J.A., et al. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 400-406
21. Levin A.D., et al. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9463-9467
22. Hwang C.W., et al. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation 111 (2005) 1619-1626
23. Finn A.V., et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112 (2005) 270-278
24. Ribichini F.J.M., et al. Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis. J. Am. College Cardiol. 50 (2007) 176-185
25. Lagerqvist B., et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N. Engl. J. Med. 356 (2007) 1009-1019
26. Moses J.W., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349 (2003) 1315-1323
27. Stone G.W., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350 (2004) 221-231
28. McFadden E.P., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 (2004) 1519-1521
29. Kuchulakanti P.K., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113 (2006) 1108-1113
30. Pfisterer M., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 48 (2006) 2584-2591
31. Oyabu J., et al. Angioscopic evaluation of neointima coverage: sirolimus drug-eluting stent versus bare metal stent. Am. Heart J. 152 (2006) 1168-1174
32. Ge L., et al. Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation. J. Am. Coll. Cardiol. 46 (2005) 613-620
33. Goodall A. Role of shear stress and turbulence on platelets in blood conduits and on endothelial cells in arterial conduits. In: Sigwart U. (Ed). Endoluminal Stenting (1996), WB Saunders Co. Ltd. 65-78
34. LaDisa Jr. J.F., et al. Alterations in regional vascular geometry produced by theoretical stent implantation influence distributions of wall shear stress: analysis of a curved coronary artery using 3D computational fluid dynamics modeling. Biomed. Eng. Online 5 (2006) 40
35. Mintz G.S., and Weissman N.J. Intravascular ultrasound in the drug-eluting stent era. J. Am. Colloid Cardiol. 48 (2006) 421-429
36. Farb A., et al. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 108 (2003) 1701-1706
37. Farb A., et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation 105 (2002) 2974-2980
38. Luscher T.F., et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115 (2007) 1051-1058
39. Steffel J., et al. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 113 (2006) 722-731
40. Virmani R., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 (2004) 701-705